In BMIs Q210 Business Environment Ratings for the 17 countries of the MEA region, Bahrain has moved up one place to take fifth spot. This is despite the country's overall pharmaceutical market rating dropping by 1.5 points. However, due to the precipitous drop from South Africa falling 4 places and 4.5 points Bahrain has managed to edge up in the rankings. The potential returns from the market are constrained by the islands population of just 1mn. However, the low-risk economic and political climate and strong pharmaceutical-specific regulatory framework mean that Bahrain is one of the regions most attractive markets in terms of the risks to realisation of returns category.
Key Topics Covered:
Executive Summary
SWOT Analysis
Pharmaceutical Business Environment Ratings
Bahrain Market Summary
Regulatory Regime
Industry Developments
Industry Forecast Scenario
Competitive Landscape
Company Monitor
Country Snapshot: Bahrain Demographic Data
Methodology
Forecast Tables
Companies Mentioned:
Al-Jishi Corporation Bahrain Industrial Pharmaceutical Co (Bidapharm) Behzad Medical Establishment Yousuf Mahmood Husain Company GlaxoSmithKline (GSK) Novartis Johnson & Johnson (J&J) Merck & Co Pfizer Sanofi-Aventisresearchandmarkets